Despite optimized design, this study has limitations: (1) External validation of CHST11’s prognostic features relied mainly on public databases, with potential selection bias due to pancreatic cancer heterogeneity and incomplete pathological subtype coverage; future studies should include subgroup and pathological subtype-specific analyses. This evidence concerns the gene CHST11 and familial pancreatic carcinoma.